Evidence map›Paper›PMID 32708236›Full record

ArticleMolecules (Basel, Switzerland)2020

Synthesis, Characterization, and Biologic Activity of New Acyl Hydrazides and 1,3,4-Oxadiazole Derivatives.

Irina Zarafu, Lilia Matei, Coralia Bleotu, Petre Ionita, Arnaud Tatibouët, Anca Păun, Ioana Nicolau, Anamaria Hanganu, Carmen Limban, Diana Camelia Nuta and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. A newFuture microbiology · 2025
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Irina ZarafuFaculty of Chemistry, University of Bucharest, 050663 Bucharest, Romania.
Lilia Matei"Stefan S Nicolau" Institute of Virology, Romanian Academy, 030304 Bucharest, Romania.
Coralia Bleotu"Stefan S Nicolau" Institute of Virology, Romanian Academy, 030304 Bucharest, Romania.
Petre IonitaFaculty of Chemistry, University of Bucharest, 050663 Bucharest, Romania.ORCID 0000-0002-2216-3842
Arnaud TatibouëtInstitute of Organic and Analytical Chemistry ICOA-UMR7311, University of Orleans, 45067 Orleans, France.
Anca PăunFaculty of Chemistry, University of Bucharest, 050663 Bucharest, Romania.
Ioana NicolauFaculty of Chemistry, University of Bucharest, 050663 Bucharest, Romania.
Anamaria HanganuResearch Institute of the University of Bucharest (ICUB), Life, Environmental and Earth Sciences Division, University of Bucharest, 060023 Bucharest, Romania.ORCID 0000-0002-0433-752X
Carmen LimbanFaculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Diana Camelia NutaFaculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Roxana Maria NemeșNational Institute of Pneumology Marius Nasta, 050152 Bucharest, Romania.
Carmen Cristina Diaconu"Stefan S Nicolau" Institute of Virology, Romanian Academy, 030304 Bucharest, Romania.
Cristiana RadulescuFaculty of Sciences and Arts, "Valahia" University of Targoviste, 130004 Targoviste, Romania.ORCID 0000-0003-1208-7732
University of Bucharest · ROCarol Davila University of Medicine and Pharmacy · ROInstitutul de Pneumoftiziologie "Marius Nasta" · RORomanian Academy · ROUniversité d'Orléans · FRValahia University of Targoviste · RO

Funding

Ministry of Education and Research CNFIS-FDI-0397 Performanţă şi excelenţă în cercetarea multidisciplinară (PerExcel) [Performance and excellence in multidisciplinary research] 2020Ministry of European Funds Competitiveness Operational Programme (COP) A1.1.4. ID: P_37_798 MyeloAL-EDiaProT, Contract 149/26.10.2016, (SMIS: 106774), MyeloAL Project
6 · The paper itself

Abstract

Starting from isoniazid and carboxylic acids as precursors, thirteen new hydrazides and 1,3,4-oxadiazoles of 2-(4-substituted-phenoxymethyl)-benzoic acids were synthesized and characterized by appropriate means. Their biological properties were evaluated in terms of apoptosis, cell cycle blocking, and drug metabolism gene expression on HCT-8 and HT-29 cell lines. In vitro antimicrobial tests were performed by the microplate Alamar Blue assay for the anti-mycobacterial activities and an adapted agar disk diffusion technique for other non-tubercular bacterial strains. The best antibacterial activity (anti-

Indexed as

Anti-Infective AgentsAntineoplastic AgentsAntitubercular AgentsArylamine N-AcetyltransferaseBenzoatesCarboxylic AcidsDrug Evaluation, PreclinicalG1 PhaseGene Expression RegulationHumansHydrazinesIsoniazidMicrobial Sensitivity TestsMycobacterium tuberculosisOxadiazolesRNA, Messenger1,3,4-oxadiazoleAnti-Infective AgentsAntineoplastic AgentsAntitubercular AgentsArylamine N-AcetyltransferaseBenzoatesCarboxylic AcidsHydrazinesIsoniazidNAT2 protein, humanOxadiazolesRNA, Messengerantibacterial activityapoptosiscell cycledrug metabolism genes expressionisoniazidoxadiazolesynthesis

Identifiers

PMID32708236
PMCPMC7396991
OpenAlexW3044493654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.